Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>PK profile for EnaV and MMAE in the dose-escalation phase. Plasma/serum concentrations of (<b>A</b>) conjugated EnaV and (<b>B</b>) MMAE at Q3W. Dots indicate observed data; lines indicate mean data. LLOQ, lower limit of quantitation.</p>
Saved in:
Similar Items
-
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025) -
Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
by: Kristoffer Staal Rohrberg (15009138)
Published: (2025)